Revvity, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
Revvity, Inc. reported a 4% revenue increase in fiscal year 2025, driven by Diagnostics and Software, but faced declines in net income and gross margins due to tariffs and restructuring costs.
NYSE
Revvity's fiscal year 2024 saw a slight revenue increase despite challenging market conditions, driven by growth in Diagnostics offsetting a decline in Life Sciences.
NYSE
Revvity Inc.'s 2023 10-K filing reveals a year of strategic portfolio transformation, including the divestiture of the Applied, Food and Enterprise Services businesses, and a focus on core Life Sciences and Diagnostics segments.